

WHAT CLINICIANS WANT TO KNOW

Addressing the Most Common Questions
Regarding the Clinical Management of
Non-Hodgkin Lymphoma and
Chronic Lymphocytic Leukemia



Proceedings from a Satellite Symposium Preceding the 51st ASH Annual Meeting

Moderator

Neil Love, MD

Co-Chair

Stephanie A Gregory, MD

Faculty

Jonathan W Friedberg, MD

Fredrick B Hagemester, MD

David G Maloney, MD, PhD

Kanti R Rai, MD

Wyndham H Wilson, MD, PhD



Subscribe to Podcasts or download
MP3s of this program at
ResearchToPractice.com/ASH10

From the publishers of:

**Hematologic
Oncology™**
UPDATE



What Clinicians Want To Know: Addressing the Most Common Questions Regarding the Clinical Management of NHL and CLL

A Continuing Medical Education Program

OVERVIEW OF ACTIVITY

Non-Hodgkin lymphomas (NHL) constitute a heterogeneous group of lymphoproliferative disorders. NHL is an area of active research and represents a rapidly evolving field in medical oncology. Published results from ongoing clinical trials lead to the continual emergence of new therapeutic agents and strategies. To bridge the gap between research and patient care, these proceedings from a case-based CME satellite symposium at the 2009 American Society of Hematology Annual Meeting utilize the perspectives of clinical investigators, in addition to the exchange among these individuals, to apply evidence-based concepts to routine clinical care. By providing access to the latest research developments and expert opinions on the disease, this activity will assist medical oncologists, hematologists and hematology-oncology fellows in the formulation of up-to-date clinical management strategies for NHL and chronic lymphocytic leukemia (CLL).

LEARNING OBJECTIVES

- Summarize the therapeutic advances and changing practice standards in NHL and CLL, and apply this information to routine patient care.
- Apply the results of emerging clinical research to the selection of optimal systemic therapy for patients with newly diagnosed and relapsed/refractory CLL.
- Develop an algorithm for the risk-stratified induction treatment for patients with diffuse large B-cell lymphoma (DLBCL) or mantle-cell lymphoma (MCL).
- Utilize prognostic and predictive clinical and molecular markers to aid in treatment decision-making for NHL and CLL.
- Assess the evidence-based role of maintenance therapy in the management of newly diagnosed and relapsed follicular lymphoma.
- Recount the emerging data with novel agents and combinations in the treatment of relapsed follicular lymphoma.
- Counsel appropriately selected patients about participation in ongoing clinical research studies.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 1.25 *AMA PRA Category 1 Credits*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains an audio component. To receive credit, the participant should review the CME information, listen to the CD and complete the Post-test and Educational Assessment and Credit Form located in the back of this booklet or on our website at CME.ResearchToPractice.com.

This program is supported by educational grants from Genentech BioOncology/Biogen Idec and Millennium Pharmaceuticals Inc.

Last review date: March 2010; Release date: March 2010; Expiration date: March 2011

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

MODERATOR



Neil Love, MD
Editor
Hematologic Oncology Update
Research To Practice
Miami, Florida

CO-CHAIR



Stephanie A Gregory, MD
The Elodia Kehm Chair of
Hematology; Professor of
Medicine; Director, Section of
Hematology, Rush University
Medical Center/Rush University
Chicago, Illinois

FACULTY



Jonathan W Friedberg, MD
Chief, Hematology/Oncology
Division, James P Wilmot Cancer
Center; Associate Professor of
Medicine and Oncology
University of Rochester
Rochester, New York



Fredrick B Hagemester, MD
Professor of Medicine
The University of Texas
MD Anderson Cancer Center
Department of
Lymphoma/Myeloma
Houston, Texas



David G Maloney, MD, PhD
Associate Member, Clinical
Research Division, Fred
Hutchinson Cancer Research
Center; Associate Professor of
Medicine, Division of Oncology
University of Washington
Seattle, Washington



Kanti R Rai, MD
Chief, Division of Hematology-
Oncology, Long Island Jewish
Medical Center, New Hyde
Park, New York; Joel Finkelstein
Cancer Foundation Professor of
Medicine, Albert Einstein
College of Medicine
Bronx, New York



Wyndham H Wilson, MD, PhD
Senior Investigator
Chief, Lymphoma Therapeutics
Section, Metabolism Branch
Center for Cancer Research
National Cancer Institute
Bethesda, Maryland

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: **Dr Friedberg** — *Advisory Committee*: Genentech BioOncology, Lilly USA LLC; *Research Support*: Cephalon Inc, Millennium Pharmaceuticals Inc, Rigel Pharmaceuticals Inc.

Dr Gregory — *Consultant*: Amgen Inc, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Spectrum Pharmaceuticals Inc; *Research Support*: Celgene Corporation, Curatech Co, Genentech BioOncology, GlaxoSmithKline, Immunomedics Inc, Onyx Pharmaceuticals Inc; *Speakers Bureau*: Cephalon Inc, Genentech BioOncology, GlaxoSmithKline, Millennium Pharmaceuticals Inc, Spectrum Pharmaceuticals Inc. **Dr Hagemester** — *Research Funding*: Novartis Pharmaceuticals Corporation; *Speakers Bureau*: Amgen Inc, Biogen Idec, Cephalon Inc, Genentech BioOncology, Millennium Pharmaceuticals Inc. **Dr Maloney** — *Advisory Committee*: Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Lilly USA LLC, Millennium Pharmaceuticals Inc, Spectrum Pharmaceuticals Inc, Wyeth. **Dr Rai** — *Honoraria*: Bayer Pharmaceuticals Corporation, Celgene Corporation, Cephalon Inc, Genentech BioOncology, GlaxoSmithKline. **Dr Wilson** — *Advisory Committee (no remuneration provided)*: Genentech BioOncology, Millennium Pharmaceuticals Inc.

MODERATOR — **Neil Love**: Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Centocor Ortho Biotech Services LLC, Cephalon Inc, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Genzyme Corporation, GlaxoSmithKline, ImClone Systems Incorporated, Lilly USA LLC, Millennium Pharmaceuticals Inc, Monogram BioSciences Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Roche Laboratories Inc, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

POST-TEST

What Clinicians Want To Know: Addressing the Most Common Questions Regarding the Clinical Management of NHL and CLL

QUESTIONS (PLEASE CIRCLE ANSWER):

1. **Ofatumumab is an anti-CD20 monoclonal antibody that is approved for patients with CLL who are refractory to fludarabine and alemtuzumab.**
 - a. True
 - b. False
2. **The German CLL Study Group is conducting a randomized trial evaluating front-line FCR versus _____ for patients with CLL.**
 - a. Bortezomib/ofatumumab
 - b. Bendamustine/rituximab
 - c. FCR in combination with bevacizumab
3. **A study for patients with follicular lymphoma demonstrated that the advantage of prolonged rituximab therapy versus a short course persists for many years after completion of treatment.**
 - a. True
 - b. False
4. **In the United States, bendamustine has been approved for the first-line treatment of CLL.**
 - a. True
 - b. False
5. **In general, nodal follicular lymphomas tend to be more indolent than extranodal gastrointestinal follicular lymphomas.**
 - a. True
 - b. False
6. **The RESORT trial evaluated maintenance rituximab in patients with _____.**
 - a. Mantle-cell lymphoma
 - b. Diffuse large B-cell lymphoma
 - c. Indolent lymphoma
7. **In patients with diffuse large B-cell lymphoma, which of the following are independent predictors of CNS relapse?**
 - a. Involvement in two or more extranodal sites
 - b. Elevated serum lactate dehydrogenase
 - c. Neither a nor b
 - d. Both a and b
8. **The AIDS Malignancy Consortium Phase II randomized study demonstrated that _____ among patients with HIV-associated B-cell NHL.**
 - a. EPOCH-R had no increased toxicity but superior outcomes compared to EPOCH → R
 - b. EPOCH-R had increased toxicity and equivalent

Post-test answer key: 1a, 2b, 3a, 4a, 5b, 6c, 7d, 8a

EDUCATIONAL ASSESSMENT AND CREDIT FORM

What Clinicians Want To Know: Addressing the Most Common Questions Regarding the Clinical Management of NHL and CLL

Research To Practice is committed to providing valuable continuing education for oncology clinicians, and your input is critical to helping us achieve this important goal. Please take the time to assess the activity you just completed, with the assurance that your answers and suggestions are strictly confidential.

PART ONE — Please tell us about your experience with this educational activity

How would you characterize your level of knowledge on the following topics?

4 = Excellent 3 = Good 2 = Adequate 1 = Suboptimal

	BEFORE	AFTER
Outcomes of prolonged rituximab therapy in CLL	4 3 2 1	4 3 2 1
Maintenance rituximab in follicular lymphoma, MCL and DLBCL	4 3 2 1	4 3 2 1
Weekly versus twice-weekly bortezomib in NHL	4 3 2 1	4 3 2 1
Deferred initial therapy in MCL	4 3 2 1	4 3 2 1
EPOCH chemotherapy in combination with rituximab in the treatment of AIDS-related B-cell lymphoma	4 3 2 1	4 3 2 1

Was the activity evidence based, fair, balanced and free from commercial bias?

Yes No

If no, please explain:.....

Will this activity help you improve patient care?

Yes No Not applicable

If no, please explain:.....

Did the activity meet your educational needs and expectations?

Yes No

If no, please explain:.....

Please respond to the following learning objectives (LOs) by circling the appropriate selection:

4 = Yes 3 = Will consider 2 = No 1 = Already doing N/M = LO not met N/A = Not applicable

As a result of this activity, I will be able to:

- Summarize the therapeutic advances and changing practice standards in NHL and CLL, and apply this information to routine patient care.4 3 2 1 N/M N/A
- Apply the results of emerging clinical research to the selection of optimal systemic therapy for patients with newly diagnosed and relapsed/refractory CLL.4 3 2 1 N/M N/A
- Develop an algorithm for the risk-stratified induction treatment for patients with diffuse large B-cell lymphoma (DLBCL) or mantle-cell lymphoma (MCL)4 3 2 1 N/M N/A
- Utilize prognostic and predictive clinical and molecular markers to aid in treatment decision-making for NHL and CLL4 3 2 1 N/M N/A
- Assess the evidence-based role of maintenance therapy in the management of newly diagnosed and relapsed follicular lymphoma4 3 2 1 N/M N/A
- Recount the emerging data with novel agents and combinations in the treatment of relapsed follicular lymphoma4 3 2 1 N/M N/A
- Counsel appropriately selected patients about participation in ongoing clinical research studies4 3 2 1 N/M N/A

EDUCATIONAL ASSESSMENT AND CREDIT FORM (continued)

What other practice changes will you make or consider making as a result of this activity?

.....

What additional information or training do you need on the activity topics or other oncology-related topics?

.....

Additional comments about this activity:

.....

As part of our ongoing, continuous quality-improvement effort, we conduct postactivity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey.

- Yes, I am willing to participate in a follow-up survey.
- No, I am not willing to participate in a follow-up survey.

PART TWO — Please tell us about the faculty and moderator for this educational activity

	4 = Excellent	3 = Good	2 = Adequate	1 = Suboptimal	
Faculty	Knowledge of subject matter			Effectiveness as an educator	
Jonathan W Friedberg, MD	4	3	2	1	4 3 2 1
Stephanie A Gregory, MD	4	3	2	1	4 3 2 1
Fredrick B Hagemeister, MD	4	3	2	1	4 3 2 1
David G Maloney, MD, PhD	4	3	2	1	4 3 2 1
Kanti R Rai, MD	4	3	2	1	4 3 2 1
Wyndham H Wilson, MD, PhD	4	3	2	1	4 3 2 1
Moderator	Knowledge of subject matter			Effectiveness as an educator	
Neil Love, MD	4	3	2	1	4 3 2 1

Please recommend additional faculty for future activities:

.....

Other comments about the faculty and moderator for this activity:

.....

REQUEST FOR CREDIT — Please print clearly

Name:..... Specialty:.....

Professional Designation:

- MD DO PharmD NP RN PA Other.....

Medical License/ME Number: Last 4 Digits of SSN (required):

Street Address:..... Box/Suite:.....

City, State, Zip:.....

Telephone:..... Fax:.....

Email:

Research To Practice designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

I certify my actual time spent to complete this educational activity to be _____ hour(s).

Signature: Date:

To obtain a certificate of completion and receive credit for this activity, please complete the Post-test, fill out the Educational Assessment and Credit Form and fax both to (800) 447-4310, or mail both to Research To Practice, One Biscayne Tower, 2 South Biscayne Boulevard, Suite 3600, Miami, FL 33131. You may also complete the Post-test and Educational Assessment online at CME.ResearchToPractice.com.

Hematologic Oncology™

U P D A T E

Moderator	Neil Love, MD
Managing Editor and CME Director	Kathryn Ault Ziel, PhD
Scientific Director	Richard Kaderman, PhD
Senior Director, Medical Affairs	Aviva Asnis-Alibozek, PA-C, MPAS
Writers	Clayton Campbell Douglas Paley
Continuing Education Administrator for Nursing	Sally Bogert, RNC, WHCNP
Content Validation	Margaret Peng Erin Wall Gloria Kelly, PhD
Director, Creative and Copy Editing	Aura Herrmann
Creative Manager	Fernando Rendina
Graphic Designers	Jessica Benitez Jason Cunniss Tamara Dabney Deepti Nath
Senior Production Editor	Alexis Oneca
Traffic Manager	Tere Sosa
Copy Editors	Dave Amber Margo Harris David Hill Rosemary Hulce Kirsten Miller Pat Morrissey/Havlin Carol Peschke
Production Manager	Tracy Potter
Audio Production	Frank Cesarano
Web Master	John Ribeiro
Faculty Relations Manager	Melissa Vives
Contact Information	Neil Love, MD Research To Practice One Biscayne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL 33131 Fax: (305) 377-9998 Email: DrNeilLove@ResearchToPractice.com Email: CE@ResearchToPractice.com
For CME/CNE Information	

Copyright © 2010 Research To Practice. All rights reserved.

The compact disc, Internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Participants have an implied responsibility to use the

newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.

Hematologic Oncology™

U P D A T E

Copyright © 2010 Research To Practice.

This program is supported by educational grants from
Genentech BioOncology/Biogen Idec and Millennium Pharmaceuticals Inc.

Research To Practice®

Sponsored by Research To Practice.

Last review date: March 2010

Release date: March 2010

Expiration date: March 2011

Estimated time to complete: 1.25 hours